These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 17530027)

  • 1. Targeting death-inducing receptors in cancer therapy.
    Takeda K; Stagg J; Yagita H; Okumura K; Smyth MJ
    Oncogene; 2007 May; 26(25):3745-57. PubMed ID: 17530027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TRAIL apoptotic pathway in cancer onset, progression and therapy.
    Johnstone RW; Frew AJ; Smyth MJ
    Nat Rev Cancer; 2008 Oct; 8(10):782-98. PubMed ID: 18813321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
    Cretney E; Takeda K; Smyth MJ
    Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
    Wang S
    Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRAIL death receptors and cancer therapeutics.
    Huang Y; Sheikh MS
    Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAILing death in cancer.
    Mellier G; Huang S; Shenoy K; Pervaiz S
    Mol Aspects Med; 2010 Feb; 31(1):93-112. PubMed ID: 19995571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
    Ashkenazi A; Holland P; Eckhardt SG
    J Clin Oncol; 2008 Jul; 26(21):3621-30. PubMed ID: 18640940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of established tumors in mice by a combination antibody-based therapy.
    Uno T; Takeda K; Kojima Y; Yoshizawa H; Akiba H; Mittler RS; Gejyo F; Okumura K; Yagita H; Smyth MJ
    Nat Med; 2006 Jun; 12(6):693-8. PubMed ID: 16680149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
    van der Sloot AM; Tur V; Szegezdi E; Mullally MM; Cool RH; Samali A; Serrano L; Quax WJ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8634-9. PubMed ID: 16731632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
    Wagner KW; Punnoose EA; Januario T; Lawrence DA; Pitti RM; Lancaster K; Lee D; von Goetz M; Yee SF; Totpal K; Huw L; Katta V; Cavet G; Hymowitz SG; Amler L; Ashkenazi A
    Nat Med; 2007 Sep; 13(9):1070-7. PubMed ID: 17767167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
    Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting of CD95 and the TRAIL death receptors.
    Gerspach J; Pfizenmaier K; Wajant H
    Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):294-310. PubMed ID: 21762072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
    Gasparian ME; Chernyak BV; Dolgikh DA; Yagolovich AV; Popova EN; Sycheva AM; Moshkovskii SA; Kirpichnikov MP
    Apoptosis; 2009 Jun; 14(6):778-87. PubMed ID: 19412666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Death to the bad guys: targeting cancer via Apo2L/TRAIL.
    Bouralexis S; Findlay DM; Evdokiou A
    Apoptosis; 2005 Jan; 10(1):35-51. PubMed ID: 15711921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
    Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
    Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into apoptosis signaling by Apo2L/TRAIL.
    Gonzalvez F; Ashkenazi A
    Oncogene; 2010 Aug; 29(34):4752-65. PubMed ID: 20531300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NO TRAIL to YES TRAIL in cancer therapy (review).
    Lee JY; Huerta-Yepez S; Vega M; Baritaki S; Spandidos DA; Bonavida B
    Int J Oncol; 2007 Oct; 31(4):685-91. PubMed ID: 17786298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.